🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06526442
Recruiting Observational

MRE for Diagnosis of Pancreatic Masses

NCT06526442 · tracked via the Priya Life Science China tracker
Sponsor
Yu Shi
Phase
Observational
Started
2020-10-09
Last updated
2026-02-13

Condition(s) studied

Pancreatic NeoplasmMagnetic Resonance Imaging

Investigational drug(s) / intervention(s)

magnetic resonance imaging

magnetic resonance imaging: all participants undergo novel MR sequences, including 3D-MRE,DCE-MRI,IVIM-DWI,T1/T2 mapping.

Study summary

Pancreatic ductal adenocarcinoma (PDAC) accounts for 85-95% of pancreatic cancer and is one of the deadliest tumors in the world, with a survival rate of less than 8%, and identifying key prognostic or predictive factors facilitates risk stratification and prospective assessment in clinical trials. The extracellular matrix (ECM) surrounding PDAC often exhibits a large number of interstitial fibrosis, which is closely related to the formation, development and metastasis of PDAC. High order three-dimensional MR elastography (3D-MRE) allows non-invasive measurements of sheer stiffness in normal pancreas and pancreatic lesions. However, there are no reports about the application of MRE imaging biomarkers to predict the prognosis of PDAC at home and abroad.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. granting of written informed consent 2. age ≥18 years 3. no history of extrapancreatic malignancy 4. no preoperative biliary drainage 5. definitive histologic evidence of PDAC in excisional biopsy 6. with no less than three months of postoperative mortality or six months of follow- up Exclusion Criteria: 1. inability to re-review of tissue specimens 2. unacceptable estimates of MRE parameters, specifically invalid wave data during postprocessing, inconsistent breath-holdings, intolerable pain, and MRE hardware disconnection 3. tumor diameters \<1.0 cm 4. withdrawal/dropout during follow-up

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shengjing hospital of china medical university Shenyang Liaoning Recruiting

More Yu Shi trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06526442 on ClinicalTrials.gov ↗ ← All trials in China